• Login
    • Library Home
    View Item 
    •   BracU IR
    • Brac Business School (BBS)
    • Internship Report, BBA (Brac Business School)
    • View Item
    •   BracU IR
    • Brac Business School (BBS)
    • Internship Report, BBA (Brac Business School)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Factors behind exiting from the Bangladesh pharmaceutical industry and closing down the pharma businesses unit of GlaxoSmithKline Bangladesh Ltd.

    Thumbnail
    View/Open
    16104124_BBA.pdf (1.717Mb)
    Date
    2018-12
    Publisher
    BRAC University
    Author
    Islam, Md. Saiful
    Metadata
    Show full item record
    URI
    http://hdl.handle.net/10361/11092
    Abstract
    The pharmaceutical industry in Bangladesh has been increasing in recent years and currently, the market stands at 142 billion BDT. Demand for good quality drugs is on the rise and the local market demand will to reach BD 160 billion BDT by 2018. Bangladesh pharmaceutical companies supply generic products and can charge premiums for their products. The top 10 companies have about 67% of the market. It is very complicated to enter this sector due to a high investment. GlaxoSmithKline Bangladesh Ltd is one of the renowned pharmaceutical company, listed on the Dhaka Stock Exchange, and has been successful in the stock market. The company has a very high dividend payment rate that primarily attracts the company's shareholders. The profitability of this company declined from 2016 to 2017. The company has a very low current ratio that could pose a threat to it. Therefore, the company should focus more on this problem and should be careful to monitor the debts. Although, after comparing the financial report with other pharmaceuticals found that GSK had a good financial performance because of the performance of their consumer health sector. On the other hand, sales of the pharmaceutical unit are shrinking as they could not cope up with the rivals and failure to match the current market demand leads to a decrease in sales. Therefore, that may lead their pharmaceutical business unsustainable. The pharmaceutical unit is incurring losses for the last three years consecutively. Hence, the GSK shareholders and board of directors decide to close the pharmaceutical business unit and continue their operation in Bangladesh with consumer healthcare business, which is profitable. Therefore, the aims are to identify the factors that influence GSK Bangladesh Ltd. to close down its pharmaceutical business unit in Bangladesh although the industry is growing at 15% more than GDP growth rate of the country. It also focuses on the processes that need to give attention as a multinational pharmaceutical company while existing from Bangladeshi market.
    Keywords
    GlaxoSmithKline Bangladesh Limited; Pharmaceuticals
     
    Description
    This internship report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Business Administration, 2018.
     
    Cataloged from PDF version of internship report.
     
    Includes bibliographical references (page 40-41).
    Department
    BRAC Business School, BRAC University
    Collections
    • Internship Report, BBA (Brac Business School)

    Copyright © 2008-2019 Ayesha Abed Library, Brac University 
    Contact Us | Send Feedback
     

     

    Policy Guidelines

    • BracU Policy
    • Publisher Policy

    Browse

    All of BracU Institutional RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    View Usage Statistics

    Copyright © 2008-2019 Ayesha Abed Library, Brac University 
    Contact Us | Send Feedback